DEZHAN HEALTHCARE(000813)2024-10-30 12:44Financial Performance - Revenue for Q3 2024 was CNY 106,155,066.27, a decrease of 7.15% compared to the same period last year[1] - Net profit attributable to shareholders was CNY -2,063,082.26, representing a decline of 102.99% year-on-year[1] - Net profit excluding non-recurring items was CNY -3,290,961.45, down 70.35% from the previous year[1] - Cash flow from operating activities was CNY -25,080,901.14, a decrease of 122.47% compared to the same period last year[1] - Total operating revenue for Q3 2024 reached CNY 354,472,693.30, an increase of 5.9% compared to CNY 335,143,687.81 in the same period last year[21] - Net profit for the period was CNY -962,035.15, a significant decrease from CNY 48,452,894.63 in the previous year, indicating a shift to a loss[22] - The total comprehensive income attributable to the parent company was 8,089,554.12 yuan, compared to 61,365,294.29 yuan in the previous period, indicating a significant decline[23] - The company reported a basic and diluted earnings per share of 0.0037 yuan, compared to 0.0281 yuan in the previous period[23] Assets and Liabilities - Total assets as of September 30, 2024, were CNY 5,299,799,872.06, down 1.47% from the end of the previous year[1] - The total assets as of the end of Q3 2024 were CNY 5,299,799,872.06, compared to CNY 5,378,612,557.62 at the end of the previous quarter[20] - Total liabilities increased to CNY 139,599,759.03 from CNY 137,145,270.06, reflecting a rise of 1.8%[20] - The company's total equity decreased to CNY 5,160,200,113.03 from CNY 5,241,467,287.56, indicating a decline of 1.6%[20] Cash Flow - The net cash flow from operating activities was -25,080,901.14 yuan, a decrease from 111,632,734.66 yuan in the same period last year[25] - Cash inflow from operating activities totaled 372,845,207.31 yuan, down from 494,681,426.00 yuan year-over-year[24] - The net cash flow from investing activities was -110,143,377.46 yuan, a decrease from 249,470,398.54 yuan in the previous year[25] - Cash and cash equivalents at the end of the period amounted to 2,531,158,919.42 yuan, down from 2,784,473,389.92 yuan at the end of the previous period[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 51,038[6] - The largest shareholder, Shanghai Yueye Equity Investment Management Partnership, holds 19.13% of shares, totaling 414,138,066 shares[6] - The second-largest shareholder, Xinjiang Kaidi Investment Co., Ltd., holds 18.93% of shares, totaling 409,748,445 shares, with 193,000,000 shares pledged[6] - The third-largest shareholder, Merrill Holdings Group, holds 13.57% of shares, totaling 293,730,162 shares, which are frozen[6] - The top ten shareholders account for a significant portion of the total share capital, with the largest three shareholders alone holding over 51%[11] Share Repurchase and Future Plans - The company expects a net profit attributable to shareholders of 8 million to 12 million RMB for the first half of 2024, with a net profit of 6.5 million to 9.5 million RMB after deducting non-recurring gains and losses[14] - The company plans to repurchase shares with an amount not less than 200 million RMB and not exceeding 300 million RMB[14] - The company has a total of 24,176,500 shares held in the repurchase special securities account, accounting for 1.12% of the total share capital[13] - The company plans to repurchase shares at a price not exceeding RMB 3.59 per share, with a total repurchase amount between RMB 200 million and RMB 300 million[16] - As of September 10, 2024, the company has repurchased a total of 21,649,500 shares, accounting for 1.00% of the total share capital, with a total transaction amount of RMB 53,814,234[16] Impairment and Other Financial Issues - The company has recognized an asset impairment provision of RMB 10.44 million for the first half of 2024 due to indications of impairment in accounts receivable and inventory[16] - The company is involved in litigation due to contractual disputes with former controlling shareholder Meilin Holdings Group Co., Ltd., and other related parties[17] - The company has not yet received the performance compensation from Meilin Holdings as per the performance commitment agreement, leading to arbitration proceedings initiated by Kaidi Investment[16] Operational Metrics - The company experienced a decrease in sales revenue from 468,449,864.07 yuan to 346,545,223.78 yuan year-over-year[24] - Total operating costs amounted to CNY 333,494,551.73, up from CNY 328,972,818.54, reflecting a year-over-year increase of 1.6%[21] - Research and development expenses for Q3 2024 were CNY 36,148,711.02, slightly down from CNY 37,686,122.01 in the prior year[22] - The company reported a decrease in sales expenses to CNY 61,587,510.18 from CNY 65,687,800.69, a reduction of 6.4%[21] Other Financial Information - The company has reported a change in shareholding due to judicial enforcement, with Merrill Holdings having 21,649,438 shares executed, resulting in a change of over 1% in their holdings[14] - The company has not disclosed any other significant shareholder relationships or actions beyond those mentioned[11] - The company's inventory as of September 30, 2024, was RMB 210,732,288.05, slightly up from RMB 207,560,244.65 at the beginning of the period[18] - The company's other receivables slightly increased to RMB 323,887,686.97 from RMB 322,201,651.98 at the beginning of the period[18] - Deferred income tax assets increased to CNY 22,282,509.32 from CNY 15,046,330.90, showing a growth of 48.3%[19] - The company's cash and cash equivalents as of September 30, 2024, amounted to RMB 2,628,102,317.69, a decrease from RMB 2,796,417,277.38 at the beginning of the period[18] - The report for the third quarter was not audited[26]